NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

by Vandana Singh, Benzinga Editor

July 7, 2021 8:06 AM | 1 min read |

NextCure Inc NXTC has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody.
The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.
After a recommended dose for the Phase 2 portion of the trial is determined, NC762 will be evaluated in select tumor types.
A B7-H4 Immunohistochemistry (IHC) assay has been developed and will be used for patient selection in Phase 2.
Price Action: NXTC shares closed at $7.89 on Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.